January 12, 2018 / 4:57 PM / 5 months ago

BRIEF-ICER Says Spark Therapeutics Gene Therapy Price Too High

Jan 12 (Reuters) - Spark Therapeutics Inc:

* INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW SAYS SPARK THERAPEUTICS LUXTURNA GENE THERAPY PRICE FAR TOO HIGH

* ICER SAYS $850,000 PRICE FOR LUXTURNA BLINDNESS TREATMENT SHOULD BE 75-82 PERCENT LOWER BASED ON VALUE ASSESSMENT

* ICER RECOMMENDS LUXTURNA PRICE BETWEEN $153,000 AND $217,000 FOR ONE-TIME GENE THERAPY Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below